What Is Semax?

Semax is a synthetic heptapeptide (sequence: Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is derived from the ACTH(4-7) fragment (the four-amino-acid stretch of adrenocorticotropic hormone that carries most of the hormone's CNS activity without its peripheral effects). Researchers appended a Pro-Gly-Pro tripeptide to the C-terminus, the same stability approach used in Selank's development, to slow enzymatic degradation and extend its half-life in the brain.

Semax is approved as a pharmaceutical drug in Russia for cognitive impairment, recovery from ischemic stroke, and optic nerve atrophy. It is not FDA-approved or EMA-approved. In the United States it is not a scheduled substance, but it is not an approved drug — it occupies the same research-compound gray zone as most peptides on this site.

In nootropic communities, Semax is the more activating counterpart to Selank. Where Selank is described as calming and anxiolytic, Semax is described as sharpening — improved attention, mental drive, and a mild cognitive edge. The two are frequently taken together.

What Does the Research Say?

Evidence level: Preliminary — Semax has a plausible mechanism characterized in animal studies (BDNF upregulation, dopaminergic and serotonergic modulation), and clinical trials from Russian institutions that supported its pharmaceutical approval. Independent Western replication is essentially absent. The evidence base is real but geographically concentrated.

Mechanism

Semax's most consistently documented action is upregulation of BDNF (brain-derived neurotrophic factor) mRNA expression in the hippocampus, along with upregulation of trkB, the primary BDNF receptor. Dolotov et al. (2006) characterized this in rats, showing that intranasal Semax increased hippocampal BDNF and trkB gene expression within hours of administration. BDNF is central to synaptic plasticity and neuronal survival, which is why it gets invoked for both the cognitive enhancement and neuroprotection claims.

Beyond BDNF, Semax modulates dopaminergic, serotonergic, and noradrenergic systems. This is consistent with the activating quality users describe and with the attentional effects reported in clinical use. Semax also shows antioxidant activity and reduction of oxidative stress in brain tissue, particularly relevant to the stroke indication.

Unlike ACTH itself, Semax does not stimulate the adrenal glands to produce cortisol. That's the design: the 4-7 fragment retains central activity while shedding the peripheral hormonal effects.

Animal Studies

Animal research on Semax is primarily from Russian laboratory groups and covers several domains. The BDNF characterization work by Dolotov et al. is the most rigorously documented mechanistic finding in the published literature. Rodent studies have reported cognitive improvements in learning and memory tasks (Morris water maze, radial arm maze), neuroprotective effects after induced ischemia, and reduced neurological deficit scores after experimental stroke. The data is consistent within the Russian research system and has not been independently replicated by groups outside it.

The ischemia findings are particularly relevant to the stroke indication. Studies have reported smaller infarct volumes and better functional outcomes in animals treated with Semax after induced ischemic events. Whether this translates to humans at the doses used in community self-experimentation is genuinely unknown.

Human Studies

Clinical trials supporting Semax's Russian pharmaceutical approval were conducted primarily at institutions including the N.N. Burdenko Neurosurgery Institute and the Institute of Neurology of the Russian Academy of Medical Sciences. The stroke recovery indication is the most studied: trials in patients with ischemic stroke examined neurological deficit measures and cognitive recovery outcomes, and reported improvements compared to controls. Myasoedov NF and colleagues conducted much of this work.

Published trials also exist in patients with optic nerve atrophy and cognitive impairment. The methodological profile mirrors the Selank situation: small sample sizes, institutional concentration, primary publication in Russian-language journals, and trial designs that don't translate directly to Western RCT standards.

No trials from Western institutions exist for Semax. There is no FDA approval process in progress. What clinicians outside Russia know about Semax comes almost entirely from what the Russian literature reports.

Community and Anecdotal Reports

Semax has one of the higher community profiles among Russian peptides in Western nootropic spaces — r/nootropics, Longecity, and similar forums have years of user documentation. The consistent description: a noticeable cognitive effect, improved attention and mental clarity, onset within 20 to 40 minutes of intranasal administration, lasting a few hours. Users describe it as activating rather than stimulating in the caffeine sense. Clearer thinking rather than arousal.

The most commonly reported downsides are headache (particularly at higher doses), nasal irritation, and a flat feeling after the effect wears off. Some users report mood effects: slightly elevated mood in most cases, but irritability or increased anxiety in a minority. Given Semax's dopaminergic and serotonergic activity, both directions are mechanistically plausible.

The Semax + Selank combination is frequently described as complementary: Semax for focus, Selank to keep the edge from tipping into anxiety. Whether that combination is additive, synergistic, or placebo stacked on placebo has not been studied.

Common Uses

Cognitive Enhancement

This is the primary reason Western community users seek Semax. The BDNF mechanism provides a plausible biological basis. User reports of improved focus, working memory, and mental clarity are consistent enough to be taken seriously as a directional signal — though they're confounded by expectation, variable product quality, and the absence of blinded trials in healthy adults. The Russian clinical trials covered patients with existing impairment, not healthy people looking to optimize.

Stroke Recovery and Neuroprotection

Semax's most thoroughly documented indication is stroke recovery. The ischemia animal data and Russian clinical trials in stroke patients provide more support here than for general cognitive enhancement. Whether the doses and routes used in community self-experimentation match what the trials used is unknown.

Optic Nerve Disorders

Optic nerve atrophy is a specific approved indication in Russia, and published trials in this population exist within the Russian literature. This is not an indication that community users typically pursue.

Attention and Focus

Community users with attention difficulties describe Semax as providing a qualitatively different kind of focus than stimulant medications: less jittery, more sustained, without the appetite suppression. No clinical trials have examined Semax for ADHD or attention symptoms in any population.

Delivery Methods

Intranasal (Primary)

Intranasal delivery is the approved and standard route. The Russian pharmaceutical formulation is a nasal drop solution, typically at 0.1% concentration. Intranasal delivery provides direct CNS access via olfactory pathways alongside systemic absorption, bypassing gastrointestinal degradation. The Pro-Gly-Pro modification contributes to stability at the nasal mucosa.

Users report onset within 20 to 40 minutes. Nasal burning and irritation are the main practical downsides, particularly with more frequent use.

Subcutaneous Injection

Subcutaneous injection is used by a subset of community users and in some research contexts. No approved injectable formulation exists. The injectable route provides somewhat more predictable bioavailability than intranasal, though published pharmacokinetic comparison data is limited.

PEPVi does not provide dosing guidance. Dosing decisions should be made in consultation with a qualified healthcare provider.

Safety and Side Effects

The Russian clinical trial record describes Semax as well-tolerated in short-term use. Side effects in those trials were mild: headache, nasal irritation, and occasional dizziness. No serious adverse events were documented in the approval studies.

Community reports add patterns not well-captured in the clinical data. Headache is consistent with the clinical record and is more common at higher doses. Some users report mood instability — irritability or a flat affect — particularly with extended use. Given Semax's effects on dopaminergic and serotonergic systems, this is plausible, though the clinical trials did not study mood in healthy populations.

Interactions with prescribed psychoactive medications have not been studied. Users taking antidepressants, stimulants, or anxiolytics should discuss Semax with a physician before use; the overlapping mechanisms make interactions theoretically possible.

Long-term human safety data does not exist. Short-term use appears safe based on clinical trial data, but long-term effects on BDNF signaling, receptor expression, or neurotransmitter balance at therapeutic doses are genuinely unknown.

Semax is approved as a pharmaceutical drug in Russia. It is not FDA-approved, EMA-approved, or approved by any equivalent Western regulatory authority. It is not a scheduled controlled substance under US DEA regulations.

In the United States, Semax occupies the same research-compound gray territory as Selank: sold by research chemical vendors and occasionally by compounding pharmacies with "not for human consumption" labeling, without the quality control or dosing oversight of a pharmaceutical supply chain.

Semax is one of the 12 peptides targeted in the current reclassification process. For details on what changes in July 2026, see What RFK's Peptide Reclassification Means for You.

Frequently Asked Questions

They have complementary profiles rather than overlapping ones. Semax is activating — users describe improved focus, attention, and mental drive. Selank is anxiolytic — users describe reduced anxiety without sedation. Semax comes from an ACTH fragment; Selank from tuftsin. They work through different mechanisms and are often taken together because the effects pair well. See Selank: What the Research Says for more.

It's activating, but users consistently describe it as different from stimulants like caffeine or amphetamine. Onset is slower, the effect reads more as clarity than arousal, and the cardiovascular activation typical of stimulants isn't reported. The dopaminergic and noradrenergic mechanisms suggest some stimulant-adjacent properties, but the subjective profile doesn't match what most people mean by "stimulant."

Russian clinical trials in impaired populations report yes. What hasn't been studied is whether it meaningfully improves cognition in healthy adults — the population most community users represent. The BDNF mechanism is real and relevant to learning and memory. Whether it translates to measurable benefits in a normally functioning brain, at the doses being used, is not established.

Short-term: the clinical trial record is mild (headache, nasal irritation, occasional dizziness, no serious adverse events). The gaps are long-term safety data, potential interactions with psychoactive medications, and effects of frequent use on dopaminergic and serotonergic systems over time. Anyone on prescribed psychoactive medications should discuss Semax with a physician before use.

Learn More

Sources

  1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al. "Semax, an analog of ACTH(4-7) with nootropic properties, activates BDNF and trkB gene expression in the rat hippocampus." Journal of Neurochemistry, 2006. — Primary mechanistic characterization of Semax's BDNF and trkB effects in rats; the foundational paper for the neuroprotective and cognitive mechanism claims.

  2. Miasoedov NF, Skvortsova VI, Trofimova LK, Khukhlova IO. "Neuroprotective effects of Semax in the acute period of brain stroke." Zh Nevrol Psikhiatr Im S S Korsakova, 1999. — Clinical study in ischemic stroke patients; primary evidence for the stroke recovery indication and the clinical basis for Russian pharmaceutical approval.

  3. FDA. "Bulk Drug Substances Used in Compounding Under Section 503A." October 2023. — Regulatory action affecting the compounding status of peptides including Semax; the basis for current US access restrictions.